The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients

European Journal of Cancer

Volumn 86, Issue , 2017, Pages 101-105

  Eggermont, Alexander M M ^a,b   Dummer, Reinhard ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adjuvant therapy; Dabrafenib; Ipilimumab; Melanoma; Nivolumab; Randomised trials; Trametinib

Indexed keywords

ANTINEOPLASTIC AGENT; DABRAFENIB; INTERFERON; IPILIMUMAB; NIVOLUMAB; TRAMETINIB; IMIDAZOLE DERIVATIVE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL OUTCOME; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN TUMOR; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL DECISION-MAKING; EVIDENCE-BASED MEDICINE; HUMANS; IMIDAZOLES; INTERFERONS; IPILIMUMAB; MELANOMA; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXIMES; PATIENT SELECTION; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PYRIDONES; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85030178834     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.09.014     Document Type: Article

References (35)

1. Eggermont, A.M.M., Spatz, A., Robert, C., Cutaneous melanoma. Lancet 383 (2014), 816–827.
2. Ugurel, S., Röhmel, J., Ascierto, P.A., et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83 (2017), 247–257.
3. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5 (2015 May), 522–530.
4. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Prolonged survival with Ipilimumab as adjuvant in stage III melanoma. New Engl J Med 375 (2016), 1845–1855.
5. Eggermont, A.M., Adjuvant ipilimumab in stage III melanoma: new landscape, new questions. Eur J Cancer 69 (2016), 39–42.
6. Weber, J., Mandala, M., Del Vecchio, M., et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med, 2017 Sep 10, 10.1056/NEJMoa1709030 [Epub ahead of print].
7. Long, G.V., Hauschild, A., Santinami, M., et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med, 2017 Sep 10, 10.1056/NEJMoa1708539 [Epub ahead of print].
8. Balch, C.M., Gershenwald, J.E., Soong, S.-J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
9. Balch, C.M., Gershenwald, J.E., Soong, S.-J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
10. van der Ploeg, A.P., van Akkooi, A.C., Schmitz, P.I., Koljenovic, S., Verhoef, C., Eggermont, A.M., EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer 46 (2010), 2414–2421.
11. Van Akkooi, A.C.J., Nowecki, Z.I., Voit, C., et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248 (2008), 949–955.
12. Van der Ploeg, A.P.T., Van Akkooi, A.C.J., Rutkowski, P., et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29 (2011), 2206–2214.
13. Van der Ploeg, A.P., van Akkooi, A.C., Haydu, L.E., et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 50 (2014), 111–120.
14. Schachter, J., Ribas, A., Long, G.V., et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 2017 Aug 16, 10.1016/S0140-6736(17)31601-X pii: S0140-6736(17)31601-X. [Epub ahead of print].
15. Wolchok, J.D., Chiarion-Seleni, V., Gonzalez, R., et al. Overall survival with combined therapy with nivolumab and ipilimumab in melanoma. N Engl J Med, 2017 Sep 10, 10.1056/NEJMoa1708539 [Epub ahead of print].
16. Hofmann, L., Forschner, A., Loquai, C., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016 Jun), 190–209.
17. Zimmer, L., Goldinger, S.M., Hofmann, L., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016 Jun), 210–225.
18. Coens, C., Suciu, S., Vanna Chiarion-Sileni, V., et al. Phase III trial (EORTC 18071/CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results. Lancet Oncol 18:3 (2017 Mar), 393–403.
19. Schadendorf, D., Long, G.V., Stroiakovski, D., et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82 (2017), 45–55.
20. Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., Blum, R.H., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:1 (1996 Jan), 7–17.
21. Grob, J.J., Dreno, B., de la Salmonière, P., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351:9120 (1998 Jun 27), 1905–1910.
22. Eggermont, A.M.M., Suciu, S., Santinami, M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008), 117–126.
23. Eggermont, A.M., Suciu, S., Testori, A., et al. Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30 (2012), 3810–3818.
24. Eggermont, A.M.M., Suciu, S., MacKie, R., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005), 1189–1196.
25. Eggermont, A.M.M., Suciu, S., Testori, A., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48 (2012), 218–225.
26. Eggermont, A.M., Suciu, S., Rutkowski, P., et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 55 (2016), 111–121.
27. Ives, N.J., Suciu, S., Eggermont, A.M.M., et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer 82 (2017), 171–183.
28. Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., Suciu, S., Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003), 241–252.
29. Mocellin, S., Pasquali, S., Rossi, C.R., Nitti, D., Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102 (2010), 493–501.
30. Garbe, C., Peris, K., Hauschild, A., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – update 2016. Eur J Cancer 63 (2016), 201–217.
31. Leiter, U., Stadler, R., Mauch, C., et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:6 (2016), 757–767.
32. Faries, M.B., Thompson, J.F., Cochran, A.J., et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:23 (2017), 2211–2222.
33. Rozeman, E.A., Fanchi, L., van Akkooi, A.C.J., et al. (Neo-)adjuvant ipilimumab 1 nivolumab (IPI1NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses. Ann Oncol, 28(Suppl 5), 2017, 1221.
34. Menzies, A.M., Gonzalez, M., Guminski, A., et al. Phase 2 study of neoadjuvant dabrafenib + trametinib (D1T) for resectable stage IIIB/C BRAF V600 mutant melanoma. Ann Oncol, 28(Suppl 5), 2017, 1221.
35. Long, G.V., Atkinson, V., Cebon, J.S., et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 18:9 (2017 Sep), 1202–1210.